Isoschaftoside

Isoschaftoside, a C-glycosylflavonoid from Desmodium uncinatum root exudate, can inhibit the growth of germinated S. hermonthica radicles. Isoschaftoside reduces reactive oxygen species (ROS) and induces proliferation in senescent cells. Isoschaftoside activates autophagy. Isoschaftoside can be used for anti-tumor, anti-inflammatory, antioxidant, antihypertensive, hepatoprotective and nematicidal study^{[1][2][3][4][5][6]}. In Vitro:Isoschaftoside (4 μM, 12 days) suppresses ROS by reducing the expression of RAC2 and LINC00294 in senescent fibroblasts^[1].
Isoschaftoside (0.25-4 μM, 12 days) significantly increases cell proliferation in senescent fibroblasts^[1].
Isoschaftoside (1 μM, 12 days) significantly increases mitochondrial membrane potential (MMP), induces metabolic changes that restore mitochondrial function and reduces dependence on glycolysis in senescent fibroblasts^[1].
Isoschaftoside (1 μM, 12 days) reduces DNA damage and fragmentation, activates the autophagy system to clear senescent fibroblasts, reduces the expression of inflammatory factors in senescent fibroblasts^[1].
Isoschaftoside (20-600 μg/mL) possesses strong nematicidal activity against M. incognita (LC₅₀ = 323.09 μg/mL)^[2].
Isoschaftoside (1-500 μM, 24 h) reduces lipid deposition via activating autophagy flux, and suppresses the expression of light-chain 3-II (LC3-II) and SQSTM1/p62 in Palmitic acid (PA) (HY-N0830)-induced autophagy inhibition in HepG2 cells^[3].
Isoschaftoside (0.05-2 mg/mL) considerably decreases renal Na+, K+-ATPase activation in basolateral membrane of the proximal tubule from pig kidney^[4].
Isoschaftoside (0-1000 μM, 9-24 h) can suppress inflammatory responses in Lipopolysaccharides (HY-D1056) (LPS)-activated microglia^[5].
In Vivo:Isoschaftoside (20 mg/kg; i.p.; daily for 4 weeks) reverses the nonalcoholic fatty liver disease (NAFLD) and reduces hepatic steatosis in mice^[3].